MedPath

Tamoxifen Compared With Clomiphene Citrate for Women Who Had Thin Endometrium Women Under Clomiphene in a Previous Cycle

Not Applicable
Conditions
Infertility
Registration Number
NCT00449514
Lead Sponsor
Shaare Zedek Medical Center
Brief Summary

About 10-15% of all couples attempting to conceive will not become pregnant within one year. Among those, the majority will have ovulatory dysfunction, mild male infertility or unexplained infertility. The traditional first line therapy for those couples is ovulation induction or superovulation using clomiphene citrate. Probably due to anti-estrogenic effects of this agent will, some patients will have a thin endometrium as measured by sonography at the time of ovulation. This phenomenon may be associated with a lower chance to conceive. Tamoxifen is a similar molecule that has been used to clomiphene citrate that has been shown to be equally effective to clomiphene in ovulation induction. Preliminary observations showed that tamoxifen does not cause a negative effect on the endometrium as compared with clomiphene, and may increase the chance to conceive in those patients who have a thin endometrium under clomiphene.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
100
Inclusion Criteria
  • Primary or secondary infertility due to:
  • Ovulatory dysfunction
  • Mild male infertility
  • Unexplained infertility
  • Endometrium < 6 mm at time of hCG during previous treatment with clomiphene citrate
  • Age 18-35
Exclusion Criteria
  • Serious adverse effects under clomiphene citrate or known sensitivity to either tamoxifen or clomiphene citrate

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Pregnancy rate
delivery rate
Secondary Outcome Measures
NameTimeMethod
endometrium thickness
percentage of ovulation
number of follicles

Trial Locations

Locations (1)

Shaare-Zedek Medical Center

🇮🇱

Jerusalem, Israel

© Copyright 2025. All Rights Reserved by MedPath